Although gene transfer was first suggested to treat inherited monogenic disorders, at present most clinical protocols are intended to treat patients with malignant disease. Although current vector technologies profoundly limit the potential therapeutic applications of gene transfer, the technique is already being successfully used to complement longer established therapies. This article reviews current and forthcoming applications of gene transfer to treat haematological malignancies.